BALTIMORE, February 21, 2017 - Elixirgen, LLC announced that it has formed two subsidiary companies, Elixirgen Scientific, LLC and Elixirgen Therapeutics, LLC, in Q4 of 2016.
Elixirgen Scientific will focus on the development and sale of regenerative medicine products for use in both the lab and clinic. The company aims to strike at one of the industry’s top issues today - the high cost and inefficiencies in iterating research and development due to the time required to differentiate cells from human pluripotent stem cells (hPSCs) to specific human cells. Since differentiated cells are the starting material for experiments in personalized medicine or large-scale drug screening efforts, delays in this process are a significant cost to biotechnology and pharmaceutical companies working in those fields. Elixirgen Scientific’s latest Quick-TissueTM Series line of stem cell differentiation kits are an affordable, all-in-one solution that reduces differentiation time from over a month to one week - available now at elixirgenscientific.com.
Elixirgen Therapeutics is a company that is dedicated to finding cures and therapies for genetic diseases, and then developing them into drugs to treat patients. The company’s experienced team of researchers has a wide variety of specialties, enabling it to use both basic research and translational research approaches to meet its goals. Elixirgen Therapeutics’ drug development pipeline will be available soon on its website, elixirgentherapeutics.com.
Elixirgen Scientific, LLC and Elixirgen Therapeutics, LLC, are located in the Science + Technology Park at Johns Hopkins in Baltimore next to their parent company. The Science + Technology Park at Johns Hopkins is an ideal research environment that allows Elixirgen Group scientists to conduct research at state-of-the-art facilities.